Choosing The Right Ligand Binding Assay Platform For Drug Development

If you're working on biologics development, the bioanalytical platform you choose early on will follow you through every subsequent study. Ligand binding assays remain a go-to methodology for measuring large molecules in complex biological matrices, and for good reason: their sensitivity and target-specific recognition make them particularly effective when you're trying to detect trace-level analytes in messy sample types like plasma or serum.

That said, LBAs aren't a default choice you make and forget. Matrix interference is a real consideration, and your reagent quality matters more than many teams anticipate until it becomes a problem. Meanwhile, LC-MS/MS has expanded its footprint in large molecule bioanalysis, offering structural characterization and precise quantitation that complement where LBAs excel. Understanding where each platform fits, rather than treating them as competitors, is where smart bioanalytical strategy starts.

Regulatory compliance adds another layer. The platform you select shapes your validation requirements, your data package, and ultimately your timeline to submission. Getting that decision right upfront is considerably easier than course-correcting mid-program.

Access the full analysis to sharpen your platform selection criteria before your next biologics program gets underway.